87 results about "Sarcoidosis" patented technology

The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formula

A_b-X

where the group A_b comprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.

Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.

The present invention relates to the discovery, identification and characterization of nucleic acids that encode a novel protein differentially expressed within the TH2 cell subpopulation (hereinafter referred to as STIF). The invention encompasses STIF nucleotides, host cell expression systems, STIF proteins, fusion proteins, polypeptides and peptides, antibodies to the STIF protein, transgenic animals that express a STIF transgene, or recombinant knock-out animals that do not express the STIF protein, and compounds that modulate STIF gene expression or STIF activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or used to treat STIF based disorders, such as proliferative disorders and T-lymphocyte-related disorders including, but not limited to, chronic inflammatory diseases and disorders, such as Crohn's disease, reactive arthritis, including Lyme disease, insulin-dependent diabetes, organ-specific autoimmunity, including multiple sclerosis, Hashimoto's thyroiditis and Grave's disease, contact dermatitis, psoriasis, graft rejection, graft versus host disease, sarcoidosis, atopic conditions, such as asthma and allergy, including allergic rhinitis, gastrointestinal allergies, including food allergies, eosinophilia, conjunctivitis, glomerular nephritis, certain pathogen susceptibilities such as helminthic (e.g., leishmaniasis) and certain viral infections, including HIV, and bacterial infections, including tuberculosis and lepromatous leprosy.

The OX-40 antigen is characterized and claimed together with variants and derivatives thereof. Also described are binding agents for the antigen and the use of these in diagnosis and therapy. Examples of such use include a method for the selective depletion of activated CD4+ T-cells in vivo by using immunotoxins comprising an OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis as well as inflammatory bowel disease and graft-versus-host disease. This type of therapy is also beneficial for eradicating CD4+ T-cell lymphomas and alloreactive CD4+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.

Disclosed are compositions useful for treating Alzheimer's disease, atherosclerosis, arteriosclerosis, osteoarthritis and other degenerative joint diseases, Huntington's chorea, Parkinson's disease, optic atrophy, retinitis pigmentosa, macular degeneration, muscular dystrophy, aging-associated degenerative processes, asthma, dermatitis, laminitis, pemphigoid, pemphigus, reactive airway disease (e.g., COPD, IAD), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), multiple sclerosis, rheumatoid arthritis, periodontal disease, systemic lupus erythematosus, sarcoidosis, psoriasis, type I diabetes, ischemia-reperfusion injury, chronic inflammatory diseases, geriatric wasting, cancer cachexia, cachexia associated with chronic inflammation, sick feeling syndrome, and other inflammatory and/or degenerative diseases, disorders, conditions, and processes in humans and other animals. In one embodiment, the compositions include at least 4 of the following: a MMP1 inhibitor, a MMP2 inhibitor, a MMP3 inhibitor, a MMP7 inhibitor, a MMP9 inhibitor, an ADAMTS-4 inhibitor, a MMP13 inhibitor, and a MMP14 inhibitor. In another embodiment, the compositions include a curcuminoid, a polymethoxylated flavone, a catechin, and a boswellic acid.

The invention relates to a method of treating an excessive immune response including an aberrant/enhanced Th1 response by administering a helminthic parasite preparation in an amount sufficient to reduce the excessive immune response in an individual. This invention is generally directed to autoimmune diseases which involve an excessive immune response or an aberrant/enhanced Th1 response. More specifically, the present invention is directed to the treatment of Crohn's disease and ulcerative colitis, both known as IBD. While the present invention discloses specific information about the treatment of IBD, the disclosure is in no way limiting. Additionally, rheumatoid arthritis, type 1 diabetes mellitus, lupus erythematosis, sarcoidosis, multiple sclerosis, autoimmune thyroiditis, allergic rhinitis, colon polyps/colon cancer and asthma can be treated by the methods and compositions disclosed therein.

Provided herein are methods of treating, preventing and/or managing sarcoidosis by the administration of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-4-acetylaminoisoindolin-l,3-dione, alone or in combination with other therapeutics.

The present invention provides a sarcoidosis benign and malignant prediction method based on a ResNet (Residual Network)-Inception model. The method comprises the steps of: obtaining a sarcoidosis image with a tag of a known sarcoidosis area, performing preprocessing of the sarcoidosis image with the tag, and obtaining a training image data set, a verification image data set and a prediction imagedata set; establishing a sarcoidosis image classification model based on a ResNet-Inception model; and inputting the predication image data set into a final mode of the sarcoidosis image classification model based on the ResNet-Inception model, and obtaining a sarcoidosis benign and malignant prediction result of the sarcoidosis image in the prediction image dataset. The method designs a new network structure model, and can obtain sarcoidosis benign and malignant prediction according to a sarcoidosis CT image.

Compositions comprising an RNA interference (RNAi) compound complexed to or encapsulated by lipid particles are provided. The lipid particle is a lipid nanoparticle, a liposome or a combination thereof. The lipid particle comprises a cationic lipid, a phospholipid, a sterol or a tocopherol or a derivative thereof, and a conjugated lipid. The invention also provides methods for treating pulmonary diseases or disorders such as pulmonary fibrosis and sarcoidosis using the compositions comprising the RNAi-lipid particles of the invention. The methods comprise administering one or more of the RNAi compositions to the lungs of the patient in need thereof via an inhalation delivery device, for example, a nebulizer, dry powder inhaler, or a metered dose inhaler.

The invention provides a kit for detecting thyroid cancer pathopoiesia related gene variation on the basis of a high throughput sequencing technology. The kit is used for variation detection of thyroid cancer related genes, including 18 mutation sites of 6 genes comprising BRAF, NRAS, KRAS, HRAS, TERT and TP53 and 3 fusion genes comprising CCDC6/RET, NCOA4/RET and PAX8/PPARg. Online sequencing libraries are constructed by two round of multiple PCR, the specific primer is designed for target areas of the nine genes to be used in the first round of multiple PCR, and a general sequencing sequenceprimer is used in the second round of multiple PCR. The invention also discloses a kit, including primer sequences and library systems, for detecting thyroid cancer pathopoiesia related gene variation, and the kit can assist in diagnosing equivocal thyroid sarcoidosis lesions.

The invention provides adult fish feed of snake head mullets. The adult fish feed consists of the following components according to the weight parts of air-dried objects: 21-24 parts of fish meal, 3-4 parts of hydrolyzed fish protein powder, 7-9 parts of pork powder, 3-5 parts of spray-drying blood cell protein powder, 3-4 parts of shrimp meal, 4-5 parts of shrimp shell meal, 2-3 parts of euphausiid meal, 10-13 parts of fermented soybean meal, 3-5 parts of fermented cottonseed protein, 2-6 parts of peanut meal, 13-16 parts of flour, 7.5-10 parts of cassava starch, 1.5-2.5 parts of fish oil, 1-2 parts of soybean oil, 1-2 parts of soybean phospholipid oil, 1.5-2 parts of calcium dihydrogen phosphate, 1 part of a Chinese herbal medicine compound preparation and 2 parts of premixed material additives, wherein the Chinese herbal medicine compound preparation consists of the following materials according to the weight parts of the air-dried objects: 12 parts of honeysuckle flower, 10 parts of safflower, 8 parts of Indian buead, 6 parts of tuber onion seeds, 7 parts of thinleaf milkwort root-bark, 7 parts of Chinese dodder seeds and 50 parts of rice hull powder. The adult fish feed provided by the invention can be used for enhancing the immunity of the snake head mullets and preventing from infecting visceral sarcoidosis, also has a relatively good treatment effect on the snake head mullets suffering visceral sarcoidosis, and can be used for improving the survival rate of breeding of the snake head mullets.

There is disclosed a method of treating various diseases caused by micro-vasculature circulation problems, including, but not limited to, vascular insufficiency, phantom pain, diabetic neuropathy, neuropathic pain, autoimmune/inflammatory diseases (e.g., multiple sclerosis, Parkinson's disease, Crohn's Disease, lupus, rheumatoid arthritis, polymyalgia rheumatica, polymyositis, dermatomyositis, sarcoidosis), urinary retention, lymphoedema, and chronic renal insufficiency. Specifically, there is disclosed a treatment providing an effective amount of an acetyl cholinesterase inhibitor compound (or combination of compounds) to treat one or a plurality of microvasculature diseases.

The invention provides a method of alleviating a granuloma annulare or a sarcoid disease by administering to a patient having the disease, a therapeutically effective amount of an LFA-1 antagonist.

The invention provides feeds for young larimichthys crocea. The feeds consist of the following air-dried components in parts by mass: 32 to 36 parts of fish meal, 2 to 3 parts of fish protein hydrolysate powder, 3 to 6 parts of spray-dried blood cell protein powder, 3 to 6 parts of shrimp meal, 3 to 5 parts of shrimp shell meal, 4 to 8 parts of krill meal, 7 to 10 parts of silkworm chrysalis meal, 4 to 5 parts of fermented soybean meal, 1 to 1.5 parts of sesame seed meal, 2 to 3 parts of corn protein powder, 10 to 12 parts of wheat flour, 3 to 4 parts of modified cassava starch, 1 to 2 parts of kelp powder, 1.5 to 2 parts of fish oil, 1.5 to 2 parts of soybean oil, 1.5 to 2 parts of soybean phospholipid oil, 1.5 to 2 parts of calcium dihydrogen phosphate, 1 part of traditional Chinese herbal medicinal compound preparation and 2 parts of a premix additive, wherein the traditional Chinese herbal medicinal compound preparation consists of the following substances in parts by weight: 12 parts of honeysuckles, 8 parts of tuber onion seeds, 10 parts of poria cocos, 3 parts of polygala tenuifolia, 4 parts of semen cuscutae, 3 parts of safflowers and 60 parts of rice hull powder. According to the feeds, the immunity of the young larimichthys crocea can be enhanced, visceral sarcoidosis can be prevented, better treatment effects on the young larimichthys crocea suffering from visceral sarcoidosis are achieved, and the survival rate of the larimichthys crocea cultivation is increased.

The invention belongs to the technical field of medical data analysis, relating to an analysis method of grading parameters of disease-related factors, in particular to an analysis method of comprehensive grading parameters for sarcoidosis and atypical tuberculosis. The invention uses clinical epidemiology case to contrast with research approach, the patients of sarcoidosis and tuberculosis through attending confirmation of morbid biopsy and treatment are chosen to carry out retrospective analysis of single factor, the variables of risk factor, clinical feature, iconography and pathology characteristics having distinguishing meanings for the two above diseases are chosen in combination with the standards of the prior art, weighting scores of each variable is calculated, a grading model is established, and the comprehensive grading parameters for sarcoidosis and atypical tuberculosis are analyzed through a model software. The method of the invention can provide important reference basis as well as rapid and high-efficient auxiliary analysis for clinical application.

Atopic asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems in response to an allergen. Platelets play an important role in this allergic inflammatory process, by releasing preformed mediators like platelet factor 4 (PF4) and regulated upon activation in normal T cells expressed and secreted (RANTES) upon activation causing eosinophil chemotaxis. The present invention relates to allelic variants of the human Inositol polyphosphate 4-phosphatase (INPP4A) gene and splice variants of the coding sequence, which encodes INPP4A enzyme known to be an important regulator of platelet activation; and provides primers and methods suitable for the detection of these allelic variants for applications such as molecular diagnosis, prediction and prevention of an individual's disease susceptibility, and/or the genetic analysis of the INPP4A gene in a population. The invention also provides an association with the expression profile of INPP4A protein in the mouse model of asthma. Specifically, the invention provides a method for detection of predisposition to atopic disorders/other immunological disorders such as, autoimmune disorders, inflammatory disorders, cancer, multiple sclerosis, fibrosis, tuberculosis, sarcoidosis, hypertension and disorders developing due to hypertension, diabetes and disorders developing due to diabetes, alcohol abuse, anxiety, asthma, chronic obstructive pulmonary disease (COPD), cholecystectomy, degenerative joint disease (DJD), seizure disorder, arthritis, etc. where human Inositol polyphosphate 4-phosphatase (INPP4A) might play an important role due to its involvement in platelet action.

This invention identifies genes and the mRNA and polypeptide expression products of these genes which can be used as biomarkers to provide diagnostic and prognostic information in patients with sarcoidosis. These biomarkers can also be used to monitor the severity and progression of sarcoidosis and to identify drugs useful in treating the disease.

The invention belongs to the technical field of medical data analysis and relates to a method for analyzing rating parameters of relevant factors of diseases, in particular to a method for analyzing overall rating parameters of sarcoidosis and atypical tuberculosis. The method for analyzing the overall rating parameters of the sarcoidosis and the atypical tuberculosis disclosed by the invention comprises the following steps of: selecting patients with the sarcoidosis and the tuberculosis, who are confirmed by a pathologic biopsy and a treatment follow-up visit, by using a clinical epidemiology case-control study method, so as to carry out retrospective single-factor analysis; selecting variables of danger factors, clinical manifestations and characteristics of iconography and pathology, which can identify the sarcoidosis and the tuberculosis, to carry out Logistic regression analysis by combining with the conventional technical standard; calculating weight fractions of all the variables and establishing a rating model; and analyzing the overall rating parameters of the sarcoidosis and the atypical tuberculosis by using model software. The method disclosed by the invention can supply important references and a rapid and efficient auxiliary analysis for clinical application.

A method of treating disease states associated with mold and mycotoxin , resulting in illnesses such as Chronic Fatigue Syndrome (CFS), Gulf War Syndrome (GWS), fungal sinusitis, Rhino Sinusitis, Chronic Rhino Sinusitis (CRS), abnormalities in T and B cells, central and peripheral nervous system disorders, asthma, sarcoidosis, respiratory infections, fibromyalgia, headache, depression, autoimmune disorders, and cancer, among others, comprising delivery of a medication to the nasal passages and/or sinus cavities of a patient, wherein the medication comprises an antifungal agent.